First attempt to validate the gSG6-P1 salivary peptide as an immuno-epidemiological tool for evaluating human exposure to Anopheles funestus bites.


Journal Article

SUMMARY OBJECTIVE: The development of a biomarker of exposure based on the evaluation of the human antibody response specific to Anopheles salivary proteins seems promising in improving malaria control. The IgG response specific to the gSG6-P1 peptide has already been validated as a biomarker of An. gambiae exposure. This study represents a first attempt to validate the gSG6-P1 peptide as an epidemiological tool evaluating exposure to An. funestus bites, the second main malaria vector in sub-Saharan Africa. METHODS: A multi-disciplinary survey was performed in a Senegalese village where An. funestus represents the principal anopheline species. The IgG antibody level specific to gSG6-P1 was evaluated and compared in the same children before, at the peak and after the rainy season. RESULTS: Two-thirds of the children developed a specific IgG response to gSG6-P1 during the study period and--more interestingly--before the rainy season, when An. funestus was the only anopheline species reported. The specific IgG response increased during the An. funestus exposure season, and a positive association between the IgG level and the level of exposure to An. funestus bites was observed. CONCLUSIONS: The results suggest that the evaluation of the IgG response specific to gSG6-P1 in children could also represent a biomarker of exposure to An. funestus bites. The availability of such a biomarker evaluating the exposure to both main Plasmodium falciparum vectors in Africa could be particularly relevant as a direct criterion for the evaluation of the efficacy of vector control strategies.

Full Text

Duke Authors

Cited Authors

  • Poinsignon, A; Samb, B; Doucoure, S; Drame, P-M; Sarr, JB; Sow, C; Cornelie, S; Maiga, S; Thiam, C; Rogerie, F; Guindo, S; Hermann, E; Simondon, F; Dia, I; Riveau, G; Konate, L; Remoue, F

Published Date

  • October 2010

Published In

Volume / Issue

  • 15 / 10

Start / End Page

  • 1198 - 1203

PubMed ID

  • 20723184

Pubmed Central ID

  • 20723184

Electronic International Standard Serial Number (EISSN)

  • 1365-3156

International Standard Serial Number (ISSN)

  • 1360-2276

Digital Object Identifier (DOI)

  • 10.1111/j.1365-3156.2010.02611.x


  • eng